Blog
RSS FeedPosted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Apr 2025
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...
Posted by Michael Wonder on 14 Apr 2025
Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer
11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...
Posted by Michael Wonder on 10 Apr 2025
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
10 April 2025 - Today, for the first time, we have given the green light to a targeted treatment for the ...
Posted by Michael Wonder on 10 Apr 2025
Lorlatinib for the treatment of patients with advanced ALK positive non-small-cell lung cancer (review of TA909)
9 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 03 Apr 2025
Real-world evidence to support health technology assessment and payer decision making: is it now or never?
31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...
Posted by Michael Wonder on 02 Apr 2025
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A (final guidance)
2 April 2025 - NICE has published final evidence-based recommendations on the use of efanesoctocog alfa (Altuvoct) for the treatment ...
Posted by Michael Wonder on 01 Apr 2025
Pembrolizumab in combination with carboplatin and paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer
24 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Apr 2025
Nemolizumab for the treatment of patients with moderate to severe atopic dermatitis
27 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 13 Mar 2025
First licensed treatment for ultra-rare immune disorder recommended
13 March 2025 - Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome licensed for use in the ...
Posted by Michael Wonder on 13 Mar 2025
First daily pill for endometriosis approved for NHS use
13 March 2025 - Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 12 Mar 2025
Natalizumab for the treatment of patients with highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
12 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...